The debate over the patentability of isolated DNA has raged around the world. Tania Obranovich compares the two Myriad decisions from the highest courts in Australia and the US and explains how the Australian decision has called into question what had long been thought of as a fundamental pillar of Australian patent law
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
The England and Wales appeals court handed down its judgment just seven working days after hearing the trademark dispute involving pharma company Merck
Penelope Aspinall, of IP wellbeing charity Jonathan’s Voice, explains why managers should take a three-tiered approach to looking after workers’ mental health